In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
about
Upconversion nanoparticles: design, nanochemistry, and applications in theranosticsRemedial applications of silencing ribonucleic acids and modalities for its delivery to the kidneys--a reviewMicelle-like nanoparticles as carriers for DNA and siRNAsiRNA delivery to the lung: what's new?MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal CancersProgress toward in vivo use of siRNAs-IIHighly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the BrainAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors.Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixerAdvances in Systemic siRNA DeliveryThe effect of N/P ratio on the in vitro and in vivo interaction properties of PEGylated poly[2-(dimethylamino)ethyl methacrylate]-based siRNA complexes.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid TumorsIncreased tumor distribution and expression of histidine-rich plasmid polyplexes.Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agentMolecular imaging with theranostic nanoparticles.Nanoparticle PEGylation for imaging and therapy.Enhanced gene silencing through human serum albumin-mediated delivery of polyethylenimine-siRNA polyplexes.Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.Delivery of intracellular-acting biologics in pro-apoptotic therapies.Design of a platform technology for systemic delivery of siRNA to tumours using rolling circle transcription.Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics.Pancreatic cancer: gene therapy approaches and gene delivery systems.PinX1-siRNA/mPEG-PEI-SPION combined with doxorubicin enhances the inhibition of glioma growthNon-viral nanovectors for gene delivery: factors that govern successful therapeutics.Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles.Potential clinical applications of siRNA technique: benefits and limitations.RNAi-based therapeutic strategies for metabolic disease.Action and reaction: the biological response to siRNA and its delivery vehicles.Polyethylenimines for siRNA and miRNA delivery in vivo.Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy.Brain-Targeted Polymers for Gene Delivery in the Treatment of Brain Diseases.The box A domain of high mobility group box-1 protein as an efficient siRNA carrier with anti-inflammatory effects.pH-Sensitive pentablock copolymer nanocapsules as nontoxic and efficient gene carriers.Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice.Effects of dendritic core-shell glycoarchitectures on primary mesenchymal stem cells and osteoblasts obtained from different human donorsOptimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in miceNon-viral gene therapy that targets motor neurons in vivo.Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.
P2860
Q26830008-72C87018-AD9A-4569-A633-F533F1076E83Q26995395-E9C470FC-1389-4031-9D5D-809A423678BEQ27001558-770A83AD-4FD8-415C-ADFC-0E4E777A516DQ27022043-7D9A7809-FF0A-464F-9A3A-75B45F6A0949Q28076754-DC012482-5B51-4F83-B13B-E9B76BD18DA2Q28255877-684CEBD5-AC31-4F49-9E59-2D595B207B90Q28394137-64979279-048A-4047-942E-D9B6F1738284Q30275229-53CC5093-2B25-45D9-808B-B0DF87C77D74Q30403731-904CB41A-B584-47C7-8526-E829DA4E28EBQ30447306-3A295E99-2C8D-48AF-8D9E-A2276375D22DQ30581724-4EA71237-939D-4759-A90A-534A63667CEFQ33613316-3FAA0BF6-37FB-4BDB-8FF9-E3B971E91CAFQ33999411-3341C59D-2D51-4FFA-BEF1-139DEE0BC9E3Q34165321-BF94E481-8B11-4618-AD6C-73C2ECD54C59Q34566500-FE06A9AA-3822-4375-B572-AA478FECC494Q35088842-0C4F453C-D75D-417D-893C-1E358F2471C5Q35388723-021B064D-8862-4C7B-8945-93CAB85F4322Q35553193-52ADC3EF-3802-4E02-8580-7F45B19405C4Q35598122-C0154298-E6A7-421D-A9A9-98DFA0555FC0Q35778918-3A4B05F0-3845-4B55-867C-D23CB316F9F5Q36588920-C1CFD19C-4E6B-4BFC-8BF3-0F8D907DEBFAQ37031856-53946B8B-A33B-4D71-BB05-C32FC36CD741Q37467849-3B6B283D-70BA-4EE8-A6BA-904B44146456Q37621562-EAA7D6B6-211C-40EE-BB89-2C041835E6D3Q37710054-E3381263-DB14-4C8C-BBD0-A0CE53E03598Q37724374-B6673C54-CC29-4E79-996A-5BFFE955A11EQ37793079-35EDE69F-4A55-4798-87CC-946383FEEEB8Q37801965-0E7DABF0-5F93-4513-8C39-96638EEC4F3CQ37866632-9899A3EC-29B8-4D5C-92EC-C7B55080E400Q37976576-42180A0E-5CDD-4F7D-948E-0641ACF6A272Q38110474-E4CEE33B-1941-4515-8F67-473038464CA7Q38921973-0B83D5D1-1F07-494F-A27C-E5629BF38945Q39233422-17167F99-BA38-4A97-9F6C-CE3FDBFE4CCEQ39478314-9D2994D8-A358-47DC-B93F-3F4F58CD18CFQ39600368-D3A71D68-84C5-4438-A8C5-21A05981445DQ39660840-754FB105-29B1-4FC2-B687-9B6FC9609C15Q41134299-9A032653-B5F5-4FAE-800E-55ECBFF96DA7Q41507502-F0FC45EE-9D5A-4D18-B80B-70BD0336D9F0Q41760723-D7AD527B-438A-40AA-82E6-0CB110408954Q42356786-6035AF64-5331-41B2-9289-5EE8F485DC51
P2860
In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
In vivo pharmacokinetics, tiss ...... ous PEI(-PEG)/siRNA complexes.
@en
In vivo pharmacokinetics, tiss ...... ous PEI(-PEG)/siRNA complexes.
@nl
type
label
In vivo pharmacokinetics, tiss ...... ous PEI(-PEG)/siRNA complexes.
@en
In vivo pharmacokinetics, tiss ...... ous PEI(-PEG)/siRNA complexes.
@nl
prefLabel
In vivo pharmacokinetics, tiss ...... ous PEI(-PEG)/siRNA complexes.
@en
In vivo pharmacokinetics, tiss ...... ous PEI(-PEG)/siRNA complexes.
@nl
P2093
P50
P1476
In vivo pharmacokinetics, tiss ...... ous PEI(-PEG)/siRNA complexes.
@en
P2093
Anastasia Malek
Frank Czubayko
Ludger Fink
P304
P356
10.1016/J.TAAP.2009.01.014
P577
2009-01-29T00:00:00Z